Mark Gaze is a Consultant Clinical Oncologist at University College London Hospitals and Great Ormond Street Hospital for Children, posts he has held since 1993. His particular areas of expertise include the management of cancer in children and young people with radiotherapy, and the use of molecular radiotherapy in adults and children.
Mark qualified from Saint Bartholomew’s Hospital and undertook specialist cancer training in Edinburgh and Glasgow. His MD research was on the targeted radiotherapy of neuroblastoma, a subject in which he maintains a strong clinical interest. He has been the lead for radiotherapy in clinical trials run by the European Paediatric Soft Tissue Sarcoma Group (EpSSG), and also for the International Society of Paediatric Oncology European Neuroblastoma Group (SIOPEN), whose work also included quality assurance in paediatric radiotherapy. He is the Chief Investigator for two Cancer Research UK funded early phase clinical trials, one on Lutetium DOTATATE therapy of neuroblastoma, the other on intensity modulated arc radiotherapy for neuroblastoma. He is immediate past-Chairman, and remains on the Executive, of the Children’s Cancer and Leukaemia Group (www.cclg.org.uk).
He has a major interest in postgraduate medical education. He is the Lead for Continuing Professional Development and Revalidation for the Faculty of Clinical Oncology of the Royal College of Radiologists, and was formerly a member of the Faculty’s Specialist Training Board. He is a member of the RCR Council. He was formerly Chairman of the Specialty Training Committee in Clinical Oncology London, Kent Surrey and Sussex and Eastern (Essex and Hertfordshire) Deaneries.